Home›Trial›NCT07255404
🔬NCT07255404Phase 2RECRUITING

A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Study Summary

This study will enroll adults with confirmed metastatic pancreatic ductal adenocarcinoma (PDAC, systemic PDAC treatment naïve), Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, and adequate organ function. Participants will receive pumitamig (BNT327) in combination with chemotherapy.

Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions / Drugs
PumitamigNab-paclitaxelGemcitabinemFOLFIRINOX
View on ClinicalTrials.gov ↗
Sponsor
BNTX
BioNTech SE
mRNA Therapeutics
F20/100
Study Details
Enrollment105 participants
Primary Completion—
Lead SponsorBioNTech SE
Data Retrieved2026-04-11 02:55:25.057663+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.